<DOC>
	<DOCNO>NCT00021307</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I/II trial study effectiveness temozolomide plus carboplatin treating patient recurrent glioblastoma multiforme .</brief_summary>
	<brief_title>Temozolomide Plus Carboplatin Treating Patients With Recurrent Glioblastoma Multiforme</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose ( MTD ) temozolomide carboplatin patient recurrent glioblastoma multiforme . II . Determine toxic effect regimen patient . III . Determine pharmacokinetics regimen patient . IV . Determine potential either pharmacokinetic pharmacodynamic-mediated drug interaction patient treat regimen . V. Determine objective response rate stabilization rate patient treat regimen MTD . VI . Determine acute long-term toxic effect regimen MTD patient . VII . Determine time tumor progression survival patient treat regimen . OUTLINE : This dose-escalation study . Patients stratify accord age ( 50 vs 50 ) , ECOG performance status ( 0 vs 1-2 ) , prior therapy carmustine lomustine ( yes v ) . Patients receive carboplatin IV 30 minute day 1 oral temozolomide day 1-5 . Treatment repeat every 4 week total 6 course absence disease progression unacceptable toxicity . Patients stable responsive disease may receive 6 additional course temozolomide . Cohorts 1-6 patient receive escalate dos carboplatin temozolomide maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity . Additional patient treat MTD . PROJECTED ACCRUAL : Approximately 3-30 patient accrued phase I study . A total 16-58 patient accrue phase II study .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm recurrent glioblastoma multiforme Measurable disease PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Granulocyte count great 1,500/mm3 Platelet count great 100,000/mm3 Hemoglobin least 10.0 g/dL Hepatic : Bilirubin great 1.5 time normal SGOT great 3 time upper limit normal Renal : Creatinine clearance great 50 mL/min Cardiovascular : No myocardial infarction within past 6 month No congestive heart failure require therapy Other : HIV negative No active uncontrolled infection No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix No frequent vomit No medical condition would interfere oral medication intake ( e.g. , partial bowel obstruction ) No know suspect psychiatric disorder would preclude study No severe concurrent disease would preclude study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 3 month study PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent sargramostim ( GMCSF ) No concurrent prophylactic filgrastim ( GCSF ) Chemotherapy : No prior temozolomide No prior platinumbased chemotherapy Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Recovered prior major surgery No 2 week since prior subtotal tumor resection Other : Recovered prior therapy No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>